Streetbeat News

Regulatory

BMY

TSVT

2seventy bio and Bristol Myers Squibb have decided to discontinue enrollment in the Phase 3 KarMMa-9 study due to improvements in the NDMM treatment landscape and a review of the business case.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2024 | 10:03 am

ALVO

Alvotech has initiated a confirmatory patient study for AVT16, a biosimilar candidate to Entyvio (vedolizumab). This development is a significant step in Alvotech's biosimilar pipeline.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2024 | 9:05 am

AAPL

AMZN

META

FTC Chair Lina Khan warns about the potential misuse of AI by airlines for price discrimination, particularly targeting vulnerable travelers. The FTC is investigating AI's role in price discrimination, raising concerns about tech companies' data practices.

Portfolio Pulse from Benzinga Neuro

September 25, 2024 | 8:57 am

BK

COIN

BNY Mellon has received an exemption from the SEC's SAB 121 rule, allowing it to enter the cryptocurrency custody market without reflecting these assets on its balance sheet. This move could challenge Coinbase's dominance in holding assets for Bitcoin and Ethereum ETFs.

Portfolio Pulse from Aniket Verma

September 25, 2024 | 8:34 am

LEU

Centrus Energy is advocating for Congress to allocate $3.4 billion in funding towards American-made nuclear fuel technology to reduce dependency on Russian nuclear fuel. Centrus aims to expand its American Centrifuge Plant in Ohio to produce Low-Enriched Uranium (LEU) and High-Assay, Low-Enriched Uranium (HALEU) for current and next-generation reactors. This initiative requires a public-private partnership and federal investment.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2024 | 6:47 am

NVVE

Nuvve Holding Corp. has executed a 1-for-10 reverse stock split to regain compliance with Nasdaq's Bid Price Rule. The company has 652,727 shares outstanding and advises shareholders to protect their shares against market manipulation.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2024 | 6:41 am

ARQT

Arcutis Biotherapeutics announced positive results from Phase 3 trials of ZORYVE cream, showing consistent improvements in atopic dermatitis symptoms across diverse racial and skin type groups. The findings will be presented at the European Academy of Dermatology & Venereology Congress in 2024.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2024 | 6:35 am

JPM

TSLA

Elon Musk, CEO of Tesla, supports JPMorgan Chase CEO Jamie Dimon's views on border control, emphasizing the importance of controlling borders to prevent national destruction. Musk has been vocal about immigration issues, advocating for expedited legal immigration and criticizing the current U.S. immigration system.

Portfolio Pulse from Benzinga Neuro

September 25, 2024 | 5:45 am

BAC

BRK

Warren Buffett's Berkshire Hathaway has reduced its holdings in Bank of America by $863 million, bringing its stake closer to a 10% regulatory threshold. Despite the sale, Berkshire remains the largest shareholder with a $32.1 billion stake. Bank of America is expanding its retail banking presence with plans to open over 165 new financial centers by 2026.

Portfolio Pulse from Kaustubh Bagalkote

September 25, 2024 | 3:22 am

CRWD

MSFT

CrowdStrike faced scrutiny from lawmakers over a global outage caused by a software update, affecting industries worldwide. The company expressed regret and outlined measures to prevent future incidents. The outage impacted systems running Microsoft's Windows, with significant financial repercussions for Delta Air Lines.

Portfolio Pulse from Ananya Gairola

September 25, 2024 | 1:34 am